Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

November 2, 2023

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 66 min

Earnings Call Speaker Segments

Jee Hamlyn-Harris

executive
#1

Thanks, operator, and I appreciate everyone being here today as we go over Penumbra's earnings release for Q3 2023. You can find the press release along with the financial tables — including a reconciliation from GAAP to non-GAAP — under the Investors tab on our website, www.penumbrainc.com. Over the course of this call, we'll be making forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, covering things like our financial performance, commercialization efforts, clinical trials, regulatory status, quality compliance, and business trends. The figures we actually deliver could end up looking quite different from anything expressed or suggested in those forward-looking statements. That's due to a range of risks and uncertainties — among them the ones we laid out in our 10-K covering the year that closed on December 31, 2022, which we filed with the SEC. Given that, we'd advise against putting too much weight on these forward-looking statements. We also suggest you take a look at our periodic filings with the SEC, that 10-K included, since they offer a fuller picture of these factors along with other risks that might shape our future results or the market price of our stock. Penumbra accepts no obligation to update or revise our forward-looking statements, whether because of new information, future events, developments, or anything else. During today's call, some financial metrics will be discussed using a non-GAAP approach. You can find the matching GAAP figures, along with a breakdown showing how GAAP reconciles to non-GAAP, inside our press release. Adam Elsesser, who serves as Penumbra's Chairman and CEO, is going to share updates about the business. After that, Maggie Yuen, our Chief Financial Officer, will walk through what we earned and spent during the third quarter. Then Jason Mills, who holds the title Executive Vice President of Strategy, will cover the outlook we're giving for 2023. With those introductions out of the way, I'd like to hand things over to Adam Elsesser.

Adam Elsesser

executive
#2

Thanks a lot, Jee. Hello, everyone, and I appreciate you joining us for Penumbra's call covering the third quarter of 2023. Our total revenues for Q3 reached $270.9 million. That's an increase of 26.8% compared with the prior-year period as reported, or 25.9% when measured in constant currency. Sales from the thrombectomy segment worldwide set a new high of $179.1 million, climbing 38% versus the same quarter last year. Our embolization and other revenue on a global basis totaled $91.9 million, marking a 9.5% gain relative to the equivalent period a year earlier. The strongest contributor was our vascular thrombectomy operation across the globe, which grew 56.9% year-over-year, with neurothrombectomy posting a 10.3% year-over-year improvement. The U.S. The company turned in a strong quarter once again. We posted $194.8 million in revenue, a 30.9% increase from the prior-year period, driven primarily by U.S. thrombectomy overall, which climbed 42.1% year-over-year. What stands out about our thrombectomy results this quarter is that no new products were introduced — unlike what happened during the first 2 quarters of the year — demonstrating that interest continues to grow in our computer-assisted vacuum thrombectomy and stroke solutions. Looking ahead to the fourth quarter, we anticipate that total thrombectomy growth, in the United States as well as globally, will pick up a bit on a year-over-year basis, while embolization and access growth should look a lot like what we saw in the third quarter. During Q3, our gross margin rate rose to 65.6%. A combination of robust top-line gains, improved gross margins, careful spending on operating initiatives, and solid commercial performance resulted in Q3 being the most profitable period ever for our company. We achieved record non-GAAP operating income of $33.2 million, which equates to 12.3% of revenue. We hit a record for adjusted EBITDA: $51.5 million, which equals 19% of total revenue. That compares with $14.6 million last quarter and 8.9% in Q3 a year ago. On a sequential basis, our operating cash balance also grew by $27.8 million. Looking ahead, we expect substantial revenue growth, continued improvement in gross margin, higher profit margins, and strong cash flow across 2024, 2025, and beyond. Penumbra ranks as the biggest thrombectomy company globally, and our mission has always been to create proprietary technologies that remove thrombus from the body, no matter where it is located, from head to toe. Roughly two decades of steady, incremental wins have brought us to a pivotal point for both this company and the thrombectomy space. We've finally created proprietary computer-assisted vacuum thrombectomy offerings that get the best out of the three factors that matter most when clearing clots: safety, speed, and simplicity. Right now, Lightning Flash, Lightning Bolt 7, and RED 72 ascended are the engines behind our momentum. Thanks to these offerings, we're looking at hitting a remarkable milestone in Q4. Just within 2023, we expect to treat more than 100,000 people in the U.S. who are dealing with clots, through our thrombectomy portfolio. Obviously, there's still a long way to go before we can serve the 1,250,000 Americans each year who face a significant clot burden. Still, this marks a meaningful milestone for the physicians we serve along with our own staff; within vascular thrombectomy, our third quarter was robust. U.S. growth was driven strongly by Lightning Flash and Lightning Bolt 7. Now, regarding our arterial and venous divisions, we hit this benchmark with upwards of 1,200 customer accounts in total—these being hospitals utilizing either flash or bolt, so certain hospitals are tallied twice if both products are being used. Now for an update on pending accounts, which come on top of the ones I just described: last quarter we secured well over 650 new VAC approvals for flash or Bolt. Those accounts are presently moving through the usual supply chain steps before they put in their first orders. We anticipate that a large number of these customers will place orders and start using flash or bolt during this quarter. On top of that, we right now have at least 600 further accounts still moving through the initial VAC process, and we anticipate that most of them will order in Q1 or Q2 of 2024. So because of that, we expect that for the first six months of 2024, the majority of the customers we could potentially reach will have flash or bolt stocked on their shelves. Once those products are in their hands and they've started using them, we'll pivot to deepening training and expanding CAVT usage in situations where open surgery or lytic is currently the main approach. To date, reorder rates for flash and Bolt are as strong as anything we've ever brought to market in thrombectomy; in stroke thrombectomy, we're gaining share even though we already have the majority. Adoption of RED 72 with sended technology is still at an early stage, as a number of hospitals continue to move through the submission process for that product. At present, our estimate is that we hold more than 55% of the U.S. Within the aspiration catheter segment of the stroke market, our offering stands alone, whereas the rest of that market has 28 competing aspiration catheters going head-to-head. As we look forward, we believe combining our new front-end stroke procedure technology—namely RED 72 SENDit with its trackability—with our back-end procedure innovation for clot extraction, Thunderbolt, may push our share past 70% in the years ahead. Two questions come up most often among investors. First, are we able to meet the present thrombectomy opportunity? Second, what steps is Penumbra taking specifically to bring CAVT to the other 90% of patients who don't receive thrombectomy today? On your first question, I'd say yes—I believe our team understands how much work lies ahead, is capable of meeting the challenge, and will think bigger than ever before. Without getting into anything competitively sensitive, let me walk through what those efforts look like. Our attention is on three things: innovation, getting ourselves ready internally, and carrying out market access plans modeled on the approaches top-performing companies have used over the years to produce durable, sustainable growth. Starting with innovation—our pipeline there is in good shape. Physicians who are our customers, along with hospital systems, keep telling us that computer-assisted vacuum thrombectomy represents the future standard for thrombectomy. Within the coming 18 months, our plan is to introduce 4 fresh CAVT offerings across the United States. Together with flash and Bolt 7, our expectation is that this CAVT lineup will fuel gains in both market share and overall market expansion across DVT, PE and arterial. Beyond those near-term launches, we've achieved meaningful progress on next-generation technology that holds the potential to broaden the reach and strengthen the leadership of our CAVT platform across the long term. Further details on these efforts will come later; at this point, I'll note that such technologies are going to be folded into our CAVT platform, delivering distinctive advantages for the physicians we serve along with their hospitals, among them additional improvements to patient outcomes and physician usability. Internal readiness makes up the second area; we've already begun dedicated efforts toward scalable, efficient manufacturing, covering procurement of raw materials, a dependable supply chain and effective use of capacity; likewise, we've kicked off work aimed at adding still greater efficiency and scale to the teams supporting our customers and sales field, which speeds up order processing time and all time for them. And naturally, our attention is on developing our commercial organization, especially within vascular.

Adam Elsesser

executive
#3

Right now, there's a great deal competing for our team's attention: we're bringing 2 new transformative thrombectomy products to market, while also expanding our existing coronary thrombectomy offering and our embolization portfolio, which leads the market, supported by a suitable level of investment that we feel aligns nicely with our shift toward better profitability. Over the coming 2 quarters, we'll reshape the commercial team, which will put it in a stronger position to seize the thrombectomy opportunity in 2024 and beyond. Third, we're beginning to roll out a robust market access program. It draws on best-in-class historical programs centered on our computer-assisted vacuum thrombectomy platform. Inside the company, we call this effort the Penumbra CAVT initiative, and senior leaders from across the organization are guiding it, among them Dr. Jim Benenati, our Chief Medical Officer; and Dr. Ben Kaptamala, our Associate Chief Medical Officer, who are working closely with senior leaders in the clinical specialties of interventional radiology, vascular surgery, interventional cardiology and neuro intervention. Alongside leaders in our reimbursement, clinical and commercial organizations, and together with external partners, we believe this initiative will, over the long term, substantiate the advantages of our CAVT platform; with the significant work we're doing in innovation, internal readiness and market access, we are well along the path to bringing computer-assisted vacuum thrombectomy to every hospital in the United States that treats patients with blood clots in any vascular bed from head to toe, now, and internationally as these products become available in the years ahead. In fact, in the United States, where we have Lightning flash, bolt and SENDit, thrombectomy will account for roughly 67% of our domestic revenue in 2023, and we expect that figure to rise above 70% in 2024. By comparison, our thrombectomy franchise outside the U.S. will make up approximately 55% of our international sales in both 2023 and 2024, and after that we expect our new CAVT portfolio products to shape our international growth the way they do in the U.S. today. Our growth potential over the next several years is considerable, given our commercial focus on thrombectomy worldwide, along with the opportunities for profitable growth in embolization and access. And we're in the early stages of strong operating leverage even as we keep making the important investments centered on these 3 areas. The road ahead won't be a straight line, nor will it be free of challenges, but if we keep doing the right things, think bigger and work purposely. We can help many more patients while stewarding a growing profitable business over the next several years. I'll now turn the call over to Maggie to go over our financial results for the third quarter.

Maggie Yuen

executive
#4

Adam, thank you. Everyone, good afternoon. During this call, I'll walk you through the numbers we posted for Q3 2023. When I talk about revenue and gross margin, those figures are GAAP-based, while the operating expense and operating income numbers I cite are non-GAAP. Our press release contains the matching GAAP figures, plus a reconciliation of GAAP to non-GAAP, so you can refer to that. In the quarter that closed on September 30, 2023, we brought in total revenues of $270.9 million. That's a 26.8% increase as reported, and 25.9% higher in constant currency, compared with the third quarter of 2022. Geographically, our sales mix for the quarter broke down as 71.9% U.S. and 28.1% international. The U.S. On a reported basis, growth came in at 30.9%, and our regions outside the U.S. climbed 17.4% as reported and 14.3% in constant currency. The 3.6% increase we saw sequentially was driven mostly by our global thrombectomy business, which added $16.6 million, or 10.2%, and that was partly offset by a $7.1 million, or 7.2%, drop in embolization and other businesses — a decline largely tied to EMEA seasonality, the timing of immersive healthcare milestones, and the mix of our distributor customers. Turning now to revenue by franchise: our vascular business generated $171.4 million during the third quarter of 2023, which represents a 38.9% rise as reported and 38.5% in constant currency versus the same period last year, powered by a 50.2% year-over-year gain in U.S. vascular thrombectomy. In Q3 of 2023, our neuro segment brought in $99.5 million. That represents growth of 10.2% as reported and 8.5% on a constant currency basis compared with the prior-year quarter, with Europe and U.S. both turning in robust results. Moving on to gross margin, it stood at 65.6% in Q3 2023. A year earlier, in Q3 2022, it was 63.3%, and last quarter it came in at 63.8%. The quarter-over-quarter gain reflects a richer thrombectomy mix, improved labor efficiency, and a supply chain that has settled down. Our operations group keeps delivering to meet demand while concentrating on the manufacturing efforts that will unlock efficiencies down the road. Even though we're going to increase what we spend on productivity and scalability in the coming quarters, we think those costs will be balanced out by our product mix and the productivity gains we keep making in the near term, and that should let margins grow more in 2024 than they did in 2023 overall. Turning to non-GAAP operating expenses, we leave out a onetime charge related to the IPR&D acquisition, which came to $18.2 million this quarter, plus $2.4 million this quarter, the same quarter a year ago, and the prior quarter for amortization of acquired intangible assets. For the quarter, our total operating expense came to $144.5 million, which works out to 53.3% of revenue. In the same quarter a year ago, that figure stood at $127.5 million, or 59.7% of revenue, while last quarter it was $146.6 million, or 56.1% of revenue. Turning to research and development, Q3 2023 saw $21 million in expenses. That's against $21.3 million in Q3 2022 and $21.5 million in the prior quarter. SG&A for the third quarter of 2023 reached $123.5 million, equal to 45.6% of revenue. By comparison, Q3 2022 posted $106.2 million, or 49.7% of revenue, and the quarter before that came in at $125.1 million, or 47.8% of revenue. In Q3 2023, operating income came to $33.2 million, representing 12.3% of revenue. A year earlier, that figure stood at $7.8 million, or 3.7% of revenue, while the prior quarter showed $20 million, equal to 7.8% of revenue. Our investments continue to support volume growth as well as long-term initiatives that enable further organizational scaling down the road, even as we maintain prudent spending discipline at present. One item deserves mention: adjusted EBITDA, which leaves out a onetime charge of $18.2 million related to the IPR&D acquisition, along with stock compensation totaling $14.1 million this quarter, $12.8 million last quarter and $9.7 million in the year-ago period. Our adjusted EBITDA hit a record $51.5 million, which works out to 19% of total revenue. That compares with 14.6% in the prior quarter and 8.9% in the third quarter of last year. Turning now to cash flow and the balance sheet: when the third quarter closed, we had $248.9 million in cash, cash equivalents and marketable securities, with no debt on the books — that's a $27.8 million increase over the previous quarter. The quarter-over-quarter cash gain reflects stronger profitability as well as improved working capital turns. With that, I'll pass things to Jason, who will walk us through the guidance.

Jason Mills

executive
#5

Appreciate that, Maggie, and welcome, everybody, to the afternoon call. Looking ahead to Q4 of 2023, we anticipate that total company revenue growth will speed up, reaching 28% to 31% compared with the same period a year earlier — that figure lines up with the middle of the yearly guidance range we've set, which spans $1.050 billion to $1.070 billion for the whole of 2023. When it comes to thrombectomy revenue worldwide, we anticipate growth will pick up pace on a sequential basis relative to Q3, and we expect the split of sales across geographies — that is, between the United States and markets outside it — to resemble what we saw in the third quarter. At this point, I'll hand things back over to Adam so he can give the closing remarks.

Adam Elsesser

executive
#6

Appreciate it, Jason, Maggie, and Jee. Now that CAVT is gaining recognition as what thrombectomy will look like going forward, everyone here understands there's significant, meaningful work still to do. During what I said a bit earlier, I laid out the first stage of that effort. Given the chance sitting before us, we're fully committed, and we gladly take on the mission of substantially shifting how many patients gain from the technology we've created. Thanks; and thanks to you, operator. Questions can now begin.

Lilia-Celine Lozada

analyst
#7

Lilly here, filling in for Robbie. I've got two short questions, and I'll put them both out there. Why isn't the guidance being lifted by at least that amount? Is it simply a matter of being conservative, or are there other factors we ought to keep in mind for the remainder of the year? And on a related note, restating the guidance suggests a weaker fourth quarter than the street had anticipated. So what's behind that? And how should we frame our thinking about the fourth quarter?

Jason Mills

executive
#8

Yes, thanks for asking. I'll handle this one — it's Jason, and Adam can chime in if he wants to. To start, the notion that our business is set to speed up to its quickest rate this year, expanding 28% to 31% compared with a year ago, truly reflects positively on the momentum we currently have. A lot of factors go into this guidance: how far along we are and the timing of new customers securing approvals and putting their initial orders, plus the timing of new products and market development efforts. But let me offer a bit more background on the guidance. As you saw, our global thrombectomy business expanded 38% during the third quarter. Our guidance calls for worldwide thrombectomy to speed up to growth above 40% in the fourth quarter. It also calls for our U.S. thrombectomy business to expand at an even quicker clip, in the high 40% range. That said, even though our embolization and access businesses are leading franchises in their markets, those markets are more mature, so we anticipate growth there to land in the high single digits, much like the third quarter. Looking ahead, as you can likely sense throughout the organization, the growing emphasis will be on thrombectomy, where markets remain underpenetrated and where we have a platform technology in CAVT that we think will become the future standard. All in all, we're thrilled about the direction we're headed.

Lei Huang

analyst
#9

This is Lei, filling in for Larry. I've got one for Adam. Adam, you spoke not long ago about an outlook of 20% sales growth for 2024. Could you share your level of confidence in that projection? Also, what are the main drivers behind it, given the strong Q3 report you just posted? And if I could ask a follow-up: you'd previously said you expected to finish this year at mid-60% gross margin and low double-digit operating margin. Clearly, you've already reached that in Q3. So could you talk about how we should think about that as we close out the year and move into 2024?

Adam Elsesser

executive
#10

Yes. Thanks, Lei. I'll begin with the '24 guidance. We have a lot of confidence in what I actually stated at your conference — at least 20%. Our intention is to provide formal guidance on our fourth quarter call, which follows our usual pattern. At that time, we can offer the nuance surrounding that specific guidance. But clearly, based on what you're hearing from us about the business and how it's shaping up, our confidence in that at least 20% figure is obviously very high. When it comes to the profitability margin, I'll say a few words, and then Maggie can speak in more detail; running a profitable business matters greatly to us, and so does growing that profitability — something we've taken pride in for a long time. And now more than ever, I believe the world shares that view. Profitability is a measure of real importance. You heard it in the prepared remarks: we're positioning ourselves to operate this in a way that's more and more profitable; but Maggie can give you more specifics.

Maggie Yuen

executive
#11

Yeah. Our profit trajectory looks quite strong to me. What matters more, I'd say, is that we're arriving at a level of profitability we can maintain, in both gross margin and operating margin as a whole. We'll keep putting money into a range of initiatives; but like you said before, given the growing share of thrombectomy products, we keep scaling up and getting more out of our overhead; we anticipate further growth in gross margin and overall margin going forward, both for next quarter and over the longer term.

Margaret Kaczor

analyst
#12

This is Malgorzata covering for Margaret; so, another thing regarding the Q4 guidance. Clearly, you said 30% plus going into the quarter and the 28% to 31% guidance today. So — I'm just curious whether anything has shifted or perhaps that suggests some seasonal pattern; and then what does that presume about the pace of VAC approvals in Q4 compared with the prior quarter?

Jason Mills

executive
#13

Yes. Well, thanks for asking. Nothing has changed. As you're able to hear, early in the year, we discussed our guidance being $1 billion. So it has risen fairly significantly throughout the year. And — in the previous quarter, we provided an accurate assessment of how we expected the second half of the year to unfold, and nothing has changed since then. If anything, I believe you've witnessed the growth and we began to speak a bit more, I think offer you a bit more detail regarding our business from a thrombectomy versus embolization standpoint, which gives you a sense, I think, that the strength is coming perhaps even more from the thrombectomy business globally. And then clearly, in the United States, it's even stronger; so if anything, I think that's the shift in disclosure that demonstrates the strength in the business and the momentum.

Margaret Kaczor

analyst
#14

Great, that's really useful. And as a quick follow-up about how the THUNDER trial is coming along — I know last quarter I brought up that the safety endpoint needed to be changed and that roughly 75 additional patients were required. I saw that a few more patients had shown up on the clinical trials website. So I was just wondering whether the trial design had any further changes, or maybe you could comment on how Thunder Bolts has been performing in the patients enrolled so far.

Adam Elsesser

executive
#15

Yeah. No, that's a terrific question, and I appreciate it. The trial figure is roughly in the same range I had been discussing. If I recall correctly, it now stands at 275 patients. And we posted the timing on clinicaltrials.gov, which lines up broadly with what I had anticipated. Mostly — and we'll simply — we are running that trial. Enrollment looks good at the moment. What we're seeing has us fairly enthusiastic. I'll say this — the key point is that we're extremely pleased with how the product performs, and clearly that's the finest aspect of it. But beyond that product, we also have separate validation, as you're aware. There's lightning bolt, and with that comparable technology — a different catheter side — we've handled an enormous number of cases. And as everyone now sees, it's doing remarkably well. So once more, we're eager to get that to market, yet the trial has to be run, and there's only a limited amount we can do to accelerate enrollment, though things are going well so far. And as we've stated, we intend to bring this technology — the CAVT technology — to every region of the body, head to toe, so we can modernize thrombus removal and truly begin making a big dent in how many patients are suffering. Thunderbolt will be a major piece of that, and our optimism has never been stronger.

Bill Plovanic

analyst
#16

First thing, Maggie, could you help me get a handle on this — the operating margin this quarter was incredible, coming in at 12.3%. What's the right way to frame Q4? From what it sounds like, that figure will keep climbing in Q4 and on a sequential basis as we move through 2024. Then second, I'm not sure whether this ties in, particularly given that your gross margin is rising, but you brought up the sales force changes as well. I can't recall your exact wording, but the gist was that some changes are coming. Could you give us a bit more detail about what exactly you're doing? Is it a new, separate sales force aimed at different indications? Does it involve splitting up territories? Anything at all you're comfortable sharing would help us out.

Maggie Yuen

executive
#17

Okay. Thank you, Bill. Let me start with the margin, and then Adam can speak to — handle the sales force question. As I said before, the gross margin direction we're seeing, which has already improved sequentially for several quarters, is mainly the result of an ongoing shift in thrombectomy product mix, and that direction will certainly persist. I also noted that, on the whole, we keep leveraging our total capacity. I believe now is also a moment when we might speed up certain investments in our manufacturing operations. So gross margins are certainly arriving at a more settled level, though additional margin gains will still be visible in 2024. When it comes to OpEx leverage and the operating margin as a whole, we're still drawing on a great deal of the overhead and infrastructure spending we made a couple of years back, and more leverage should keep showing up as we move ahead.

Adam Elsesser

executive
#18

And Bill, Adam here. I'd like to add something regarding that particular question about the sales force. First, thank you. I believe you're all probably aware that discussing our incredible sales team and everything they've managed to achieve is something I truly enjoy; it ranks among my favorite subjects. As I explained during the call, the people we have in the field, especially within Vascular, now carry a tremendous amount of responsibility for our embolization business — which represents the bulk of the coil business in the market — along with bringing 2 game-changing products to market while also continuing to drive adoption of cataracts or coronary thrombectomy, all still grounded in the Storm-PE study from a few years back. So they are simply swamped. And at this point, we're looking at more than roughly doubling how many customers we've historically served in our thrombectomy business and working through all of that. So the key takeaway is that we intend to evolve that sales force. Splitting the sales force is not something we're doing. That isn't our strategy. What we'll do is evolve it by bringing in people capable of making some of this work more efficient, without fundamentally altering the sales team's core structure. For competitive reasons, I won't get any more granular than that. As you're aware, I don't usually disclose how many sales reps we have or how we think about that, since that isn't how we've run our team, and our team has delivered so well across the last many, many years. But we're able to do this while our profitability keeps growing. That's the most important part; this won't alter that trajectory. And my view is it will be a significant evolution of the team. but one that lets us do more without affecting that crucial profitability element.

Michael Sarcone

analyst
#19

Let's kick things off with the first question. You said that within the coming 18 months, there are 4 new CAVT products you intend to bring to market in the U.S.. I'd like to know whether you could share any details at all on that front. Do these represent new TAMs, or new indications? I'd just really appreciate a bit more detail there.

Adam Elsesser

executive
#20

Sure. That's a wonderful question. For competitive reasons, obviously, I'm quite reluctant to get into too many specifics. Having said that, I will make the following point, which is that what we believe we can deliver through our CAVT platform is only starting here, not finishing. Those 4 products are going to matter a great deal. They aren't peripheral or marginal; and that's not where it stops. We hinted at technology currently being developed that would form part of, be connected to, and be incorporated within the entire platform, which will keep pushing this field ahead and make these procedures simpler, making physicians as well as hospitals feel far more confident regarding the flow and the treatment of these patients. So we truly are at the start of this next phase, and obviously we'll provide further updates once those products receive clearance, but once again, quite enthusiastic about how the next month — next year is shaping up. And I suppose our R&D team is — it just keeps evolving. They've consistently been incredible. They've gotten us to this point, yet they are remarkable, and I must give them a quick shout out for bringing us to this stage.

Michael Sarcone

analyst
#21

Thanks. I think you also shared — you mentioned, I believe — that U.S. vascular thrombectomy sales grew 50% year-over-year. Could you discuss whatever competitive reaction you're observing, and then also what the comparable category growth was internationally for your thrombectomy business on the vascular side?

Jason Mills

executive
#22

Sure, I'll begin. Obviously, 50% growth in the U.S. for thrombectomy is many times faster than what we've witnessed anywhere else. Outside the U.S., the base is far smaller, so growth percentages can be larger from one quarter to the next; and this quarter it came in a bit above that, though that's due to distributor variance — you had a marginally strong quarter — and since the number is smaller, the percentages run bigger. Still, both regions performed well.

Richard Newitter

analyst
#23

Adam, I think you said something about wrapping up the year with those — with a thousand VAC committees working their way through the pipeline, and you expect the mall piece to be finished in the first six months of '24. Can you say a little more about that and clarify what it actually means? Should we be thinking about some kind of quantification or directional shading when it comes to growth in the first half, the second half, next year? I'm just trying to get my head around this — you're pretty thoughtful when you make those kinds of remarks; so I'm just double-checking that we're reading the message the right way.

Adam Elsesser

executive
#24

Yeah. No, I think that's genuinely on point and a really good question. Let me explain a little about what I did and what it actually means in more specific terms. So what I said was that more than 650 of those centers got approval once again in the quarter that just ended, but they haven't placed orders yet, since they're working through what we're calling — for lack of a better term — the standard supply chain process, where you collaborate with the hospital's supply chain to get the product ordered and onto the shelf and so on. So for the most part, that's going to take place for the majority of those during the current quarter. A few might slip a little, but the bulk will get done in this quarter. So once you place an order, we don't really do big stocking orders—some companies have done that over the years, but we keep it very simple. You order 1, maybe 2, and get started. Then, once you see success, you reorder the product. So we make it pretty straightforward. It's not about stocking order revenue—it's really about getting going. What I also said, there are 2 other points. One is there's another 600—over 600 hospitals that are still in the beginning of that VAC process that haven't yet had that VAC approval. After that takes place, they progress to the next group, where we need to work through the supply chain and ultimately reach the shelf. Once we've gotten to that point, once orders come in and the product can actually be utilized, our focus in those hospitals shifts—it's no longer just about the clear-cut cases where use is obvious. And if you examine—we monitor billing data at each hospital quite closely—the number of patients receiving mechanical thrombectomy compared with the number still getting lytic open surgery, which varies based on the vascular bed. That's the point at which the real effort begins, and it's exactly what I meant when I said we're ready to take that on — not just with our sales force, but through the market access efforts as well. To push this technology deeper into the hospital — and after approval arrives, we don't expect you to be at the usual run rate for our product right away; we think that will continue growing for quite a while; that's the idea I was getting across; so this is a journey. This is a process. To be clear, none of this diminishes the results we delivered this quarter. Looking ahead to the next quarter and into '24, we anticipate considerable success and considerable growth. What we'll see is that effort continuing to accumulate on a year-over-year basis for a good while. Put simply, when we consider the area of thrombus within patients' bodies — in the head, throughout the body, or down in the toe — our commitment to that area will not waver. This is where our attention lies. That's the goal we're pursuing, and we'll keep building out those markets with that aim in mind. It won't happen overnight, though we expect plenty of wins in the near term. That's the reason I put those figures in front of you. The chances we're looking at this quarter and the one after are far from small; over the longer horizon, though, my sense is they'll be considerably larger.

Richard Newitter

analyst
#25

Alright, and then for my final one, regarding those vascular thrombectomy rollouts, would you say things are exceeding or falling short of what you'd anticipated at this stage of those launches?

Adam Elsesser

executive
#26

Yeah, good question. That one's not easy to address. When it comes to our own offerings, I hold myself to a pretty demanding standard. That said, I also have faith in our technology and in the engineers who built it. So judging whether it's better or worse isn't straightforward. What I can tell you — and I keep coming back to what matters most to the physicians, and above all to the patients — is those 3 items I called out. First comes safety. The product absolutely must be safe. If it isn't, you face every kind of problem and complication imaginable. So safety — the safety characteristics of these offerings have been remarkable. That, in my view, is among the things reflected in our data, and it also comes through when you speak with physicians. Second is speed. Everybody involved in the interventional field understands that the more time a procedure takes, the more harm results; ideally it should work very fast and then you're finished. And the speed these products deliver is truly unmatched by anything we've ever created or anything that has ever reached the market. Then the last item is simplicity. It simply has to be easy and straightforward to operate. You insert the single product, with no need for several items or instruments. And that's what people have genuinely embraced. So once more, that's essentially our guiding principle, our compass. We aim to make it safe, we aim to have speed, and we aim to have it simple; and possessing that foundation now with our existing CAVT products, while recognizing we can go even further, has left us remarkably confident, and also quite energized that the upcoming stretch of time will prove very rewarding for us.

Mike Matson

analyst
#27

I'd like to ask a bit more about those 1,200 customer accounts. What portion of them had never been customers before?

Adam Elsesser

executive
#28

That's a really good thing to raise. Unfortunately, I'm not able to provide that figure with exact precision. What I can say is that, from what I know, considerably more than 50% — most of the 650 accounts, and most of the subsequent 600 — are people who came to us as new customers. A small number of those might be customers we already had, though nearly all of them are new.

Mike Matson

analyst
#29

All right; and then — what caught us off guard during '23 was simply how strong things were on the neuro side. I mean, obviously, with vascular, it seemed likely to perform well because of where we were in the product cycle. But Thunderbolt has slipped. So I'm curious, as we look toward next year, is there anything new headed into neuro that could sort of assist in pushing that growth during '24?

Adam Elsesser

executive
#30

Yeah. Let me begin with — new products are something we always have in both areas, Neuro included. I won't be discussing those. What sits at the heart of the technology today is Red 72 SENDit, and there's still plenty of runway left for it to keep fueling growth. We carry on doing that — just recently we heard about a physician who gave it a try, someone who normally had not been using our aspiration catheters, and he was especially amazed at how effectively it attracts. So I believe we brought aboard one more customer; that should fuel our success for some time since, once more, if the catheter can't be delivered there, Thunderbolt becomes irrelevant. Getting there has to be so simple that you feel eager to use Thunderbolt. So in my view, Thunderbolt's timing truly positions us so that we can use next year to keep reaching more and more accounts, which, like you mentioned, we've managed fairly well this year. We've recovered considerable share, and as I noted in my prepared remarks, by our estimate we now hold more than 55% of the stroke aspiration catheter market. And that's somewhat remarkable given that we're up against 28 other catheters. So typically, when that many products are all in competition — you don't end up with one dominant player, so to speak. And the reality that we are serves as proof of the success we've enjoyed this year with RED 72 SENDit, and I don't expect that to halt, and I believe we'll keep it going.

Jason Mills

executive
#31

Yes, Mike, that's a great question. The one point I'd like to make — Jason here — is that with SENDit, our U.S. stroke business just posted another very impressive quarter, delivering double-digit expansion, 20%. And, as you're aware, that product hasn't launched in any market beyond the U.S. yet. Another thing worth mentioning is that you're now hearing us discuss thrombectomy on a global basis, which of course encompasses stroke, spanning head to toe relative to the embolization and access businesses. So my sense is what you'll keep witnessing is thrombectomy, stroke included, but clearly vascular thrombectomy too, driving our growth. So I'm simply flagging that, since your question was about neuro versus vascular, I believe what we're really discussing is thrombectomy relative to embolization and access.

Samantha Kurtz

analyst
#32

This is Samantha sitting in for Matt. We've just got a few for you. I suppose to start, regarding the strong growth you're anticipating in thrombectomy, and you mentioned 40%. How much of that would you say comes from perhaps a simpler pre-flash comparison, as opposed to what you expect sequentially.

Jason Mills

executive
#33

Yeah. That's a really great question. I appreciate it. We still anticipate quite solid sequential growth too. Setting comparisons to one side, we are expanding much more rapidly no matter what than I believe people anticipated for thrombectomy in general and, naturally, versus the market; that's taking place on both a year-over-year basis and sequentially.

Samantha Kurtz

analyst
#34

All right. I also wanted to ask about the VACs. Thanks for providing all of that information. I'm curious whether you could share additional specifics regarding approximately how many of those records might be counted twice, once for flash and once for bolt, as opposed to only flash or only bolt.

Adam Elsesser

executive
#35

Sure. That is a great question, and I should apologize if I failed to make that clear. The way we describe them is that every single one is its own separate account. So, for instance, it's conceivable that among the 650 accounts I mentioned that have received approval again but haven't placed orders yet since they are working through the supply chain process and will do so shortly. Within that group, you could have a single hospital, yet I tally it two times since it involves bolt and flash. . And in some cases, the very same physician utilizes both products; in other cases, they don't, because, as you're aware, interventional cardiologists, vascular surgeons and interventional radiologists all share this, and some focus on particular regions of the body while others do not; therefore, a lot of those involving one hospital but 2 submissions involve distinct individuals who are championing those products. It's simply a separate process. So it isn't all combined into one, which is the reason we tally them individually. .

David Rescott

analyst
#36

David, I'd like to begin with the neuro thrombectomy segment. My sense is the year-over-year comparisons there were somewhat more difficult, and the results landed a bit under what we had anticipated. Clearly, things were stronger on the peripheral vascular side. Still, I'm curious whether there's anything you'd highlight specifically regarding neuro thrombectomy — you mentioned SENDit moving into a position where it expands the market, gains share, and perhaps delivers some pricing advantage. What I'd like to know is how that looks on a cadence basis, both year-over-year and sequentially. Can you offer any color there?

Jason Mills

executive
#37

Yes, thanks, David. Jason here. Our neuro business met the expectations we had for the quarter, and the team performed really well, particularly in the United States. In the U.S., the neuro franchise posted 17% growth year-over-year. Since the start of the year, I believe we've been saying that our vascular business would grow above the total company guidance range — which, naturally, has risen from $1 billion to its current level over the course of the year. We also indicated neuro would grow below that range. Because we don't provide specific guidance by franchise, I suspect models generally may not have factored in that guidance, possibly since neuro growth was stronger during the first half of the year. Yet we completely expected that neuro growth internationally in the second half would encounter greater seasonality and weaker growth in certain distributor markets — that's the reason we provided the guidance context we did at the beginning of the year. All told, we're very pleased with the progress in our neuro business, and we still expect the new products we have with SENDit and Thunderbolt will ultimately drive our future growth.

David Rescott

analyst
#38

All right, that's useful. Staying on that topic and pulling back to a longer horizon, I understand the newer offerings have positioned you to pick up share. Looking at the neuro thrombectomy space broadly, whether in the U.S. or globally, I recall that earlier this year a few trials reported out, specifically in thrombectomy, regarding possibly widening the market to large core patients — I think you said parked size — and more distal occlusions. So at a high level, from a macro view, I'm curious whether the neuro thrombectomy market on its own is, as I put it, reaccelerating and reexpanding, or whether those represent chances to fuel additional growth down the road.

Adam Elsesser

executive
#39

Yes, Adam here. That's a genuinely important thing to ask, so thank you for bringing it up. That opportunity — especially from the trials examining core impact, let's say parked, suggesting we might be able to treat far more patients than previously assumed — strikes me as a very big development. We haven't highlighted it in particular, since we'd rather wait and confirm that this behavior is occurring in a durable way before we allow ourselves to get overly enthusiastic; even so, I don't disagree with you. Based on everything I've been told and every discussion I've had with neuro physicians, that seems like a genuinely probable outcome. It's fairly recent; we're sort of in the summer period, so describing it as a definite, established trend is a bit premature. Still, I believe all those discussions support the idea that it might expand the market. Naturally, up to now, because of when those things occurred, the improvement we've recorded has come from share. But yes — I'd be thrilled for patients if we could treat an ever-larger number of them and they could improve. And clearly, that would deliver a very, very favorable effect on the neuro portion of our thrombectomy business.

Shagun Singh Chadha

analyst
#40

Adam, I'd love to hear your perspective on GLP-1s, specifically regarding that preclinical data looking at how GLP-1 affects peripheral artery disease. The main endpoint and the study's completion aren't expected until the middle of 2024, yet we've already witnessed movement in medtech stocks purely based on earlier top-line readouts. So anything at all you can offer us before then that would give people confidence in the PAD area would be helpful.

Adam Elsesser

executive
#41

Sure. I appreciate you asking that. Clearly, this has become a subject within the investing community, though it's less clearly one among physicians themselves. Well, here's the thing — we are the healthcare company. Any kind of innovation, in whatever shape, that helps people become healthier and feel improved, we certainly cheer for it. With that said, if you simply examine the facts, take obesity — it does not directly cause thrombus formation. It's a risk factor instead. Risk factors abound; age is one, and I could name more than 20 of them. It isn't even among the leading risk factors; nevertheless, if you looked at it and said perhaps in the very distant future you might see an impact of several percentage points on how many patients develop clots — something I'm not ready to just accept, but suppose it occurred — that wouldn't be a significant issue for our numbers, since our penetration in a market sits below 10%; and by the time such a thing materialized, it would be many, many years off, possibly even decades. The other comparison, and I believe this applies to anyone involved in stroke or any cardiovascular condition, is really statins. More than 20 years back, they carried enormous promise. And clearly they've proven quite valuable. They have — they're — they grew to be broadly used. Their usage is extremely common, and their cost has fallen dramatically, making them very, very inexpensive. Yet it hasn't, in any way — it's assisted with certain things, but it hasn't altered whatsoever how many patients have clot inside their body. It simply hasn't. So despite the other advantages it delivered, it hasn't reduced the count of patients with clot in their body one bit. Therefore, I think from the standpoint of — will we be needed as a company, and will our innovative products keep being utilized at the scale we aspire to. I believe the answer is quite obvious; we will be.

Shagun Singh Chadha

analyst
#42

Understood, that's quite useful. As a follow-up, I was hoping for more detail regarding the growth of over 20% you mentioned for '24. Should we treat that as our baseline assumption? We're still — 2024 hasn't started yet, correct? And you're also finishing the year with Q4 growth between 28% and 31%. So what does that suggest regarding '24, and is that 20%-plus figure the base case, or whatever additional detail you can offer would be great.

Adam Elsesser

executive
#43

Right. I don't want my words to be taken the wrong way by anyone. At the September investor conference, I stated that growth above 20% could be achieved. I've repeated since then, and I firmly hold that view right now. I also requested that you kindly grant us the patience and opportunity — again, this isn't about concealing anything or refusing that — to finish out this year and follow our usual practice, which is providing official guidance with precise figures during our upcoming quarterly call. Once more, please don't infer anything from that beyond me restating or confirming what I've already communicated.

Joanne Wuensch

analyst
#44

Joanne Wuensch here. If this has already come up, I’m sorry. There’s a ton happening. Did any stocking occur during the quarter? Also, could you say a bit about what you’re observing regarding — it seems like there’s some neuro softness and how that played out between the U.S. and OUS.

Adam Elsesser

executive
#45

Yeah. So, on stocking, let me handle that. We covered it briefly before, so I’ll keep it brief. Stocking isn’t something we normally do. To get folks going, our first orders are 1 or 2 units maximum; therefore that was — that isn’t how our business model works and never has been. Jason can speak to it; there was a neuro question, and Jason had already gotten that one too.

Jason Mills

executive
#46

Yeah, that's right, though I don't mind walking everyone through it. So, like I said a moment ago — and sorry to everyone else listening for repeating myself — the neuro business came in right where we thought it would this quarter. Execution was strong. To add a little more color: the neuro franchise was up 17% versus the prior year. And as you'll recall, we laid it out near the start of the year, when we first gave guidance, that vascular growth overall would outpace the company average while neuro would trail it. I think we caught some flak on that once the first half wrapped, since neuro had been performing better. But we had a handle on how our business moves. We knew there'd be more seasonality around distributor variances in neuro internationally during the back half, and that's exactly why we held our view. And sure, since we don't guide specifically to neuro doing this and vascular doing that, models probably just didn't capture it. Still, from where we sit, neuro and the neuro team are performing extremely well.

Jee Hamlyn-Harris

executive
#47

Thanks, operator. Our management team and I want to express our appreciation once more for everyone being with us today and for the attention you're giving Penumbra. We're eager to bring you up to speed during this call about our fourth quarter.

Operator

operator
#48

This concludes today's conference call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.